Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral CP-690,550 (tofacitinib) induction therapy in moderate to severe ulcerative colitis
2011-004579-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Tofacitinib induction with Placebo induction (2 arms). Primary endpoint: Remission at Week 8. Started Jan 2012; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-004579-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004579-35.